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Abstract
Breast cancer (BC) is the most common cancer and 
the second cause of death in women worldwide. 
Therapeutic options are increasing, but the response 
to treatments is not always efficient and the risk of 
recurrence covers decades. In this perspective, the 
need to have a proper follow-up for the therapeutic 
responses and for anticipating recurrence it is urgent 
in the clinical setting. Liquid biopsy provides the basic 
principle for a non-invasive method for the routinely 
monitoring of BC. However, due to the heterogeneity 
of tumors during onset and progression, the search 
for tumor DNA mutations of targeted genes in 
plasma/serum is a limiting factor. A possible approach 
overtaking this problem comes from the measurement 
of cell-free DNA integrity, which is an independent 
factor from the mutational status and theoretically is 
representative of all tumors. This review summarizes 
the state-of-the-art of cell-free DNA integrity researches 
in BC, the controversies and the future perspective. 
Key words: cfDNA integrity; Liquid biopsy; Breast cancer; 
ALU sequences; LINE-1 sequences
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Core tip: Despite the potentiality of cell-free DNA 
integrity as a useful tool for the monitoring of Breast 
Cancer (BC), evinced in some clinical studies, the 
scientific community has not reached agreeable 
conclusions to translate the results from the bench-
to-the-bedside yet. The main controversy regards 
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the targets’ choice and the size of circulating cell-free 
tumor DNA fragments. This work underlines the utility 
of cell-free DNA Integrity evaluation for BC follow-up 
and at the same time highlights the common concepts 
explaining the different results in line of future 
directions.
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INTRODUCTION
Breast cancer (BC) is still the most common cancer 
and the second cause of cancer-related death 
in women worldwide[1]. A timely knowledge of 
its occurrence, responsiveness to therapies and 
recurrence is becoming of paramount importance 
for clinicians to adopt specific and more efficient 
approaches with regards to any single patient’s health 
assistance. In clinical routine, the evaluation of serum 
markers as CEA or CA15-3 is still used for BC follow-
up, but with a low specificity and sensibility[2-5]. Up to 
now, one of the most promising frontiers in this field 
is the liquid biopsy. Recently, the meta-analysis on the 
clinical utility of circulating tumor cells (CTC) in early 
BC or in metastatic BC (MBC) provides a solid rationale 
for their use in oncological settings[6-8]. However, their 
routinely use is still compromised by the relatively high 
cost of the technique. 
Circulating cell-free DNA and qPCR measurement
From the blood circulation, it is possible to derive 
CTC, exosomes or cell-free nucleic acids (Figure 1). 
Cell-free DNA (cfDNA), consists of DNA fragments 
released after cell death processes from both tumor 
and normal cells. The circulating tumor DNA (ctDNA) 
can be differentiated from the rest of the cfDNA by 
looking at tumor-specific DNA changes, including 
mutations, gene amplifications, rearrangements and 
methylations[9] proving it as a valid non-invasive 
biomarker to monitor tumor growth, spread, clonal 
evolution and response to therapies[10]. This can be 
achieved either by a qualitative way (i.e., type of 
mutations) or quantitative way (i.e., copy number 
evaluation of mutated genes). However, the known 
mutations that can be used in liquid biopsy represent 
a limited percentage of patients. As an example, the 
most studied PI3KCA mutations all together have been 
found in about 30%-40% of BC patients[11].
Here, both low-cost and easy-to-be-perform 
methods that are not bound to one or few specific 
genetic mutations to predict occurrence and monitor 
disease progression in BC patients will be described in 
line of what is currently known in literature. 
Briefly, real-time polymerase chain reaction-or 
quantitative PCR (qPCR) is a powerful advancement of 
PCR technology that enables the measurement of the 
starting amount of nucleic acids in the reaction without 
the need for post-PCR gel analysis. This is achieved 
by the possibility to detect in a real-time manner the 
amplification process by fluorescence and to measure 
the amplification products of samples at exponential 
phases. Through this technology the expression 
of a target is measured by fluorescent probes or 
DNA-labelling dyes. Of note, the qPCR dyes do not 
discriminate between specific or non- specific amplicon 
products, thus there is a need for an accurate testing 
of the annealing conditions and buffer reagents to 
guarantee specificity of the reaction. The quantification 
of an unknown sample can be absolute by using 
an internal amplification standard curve obtained 
with known DNA quantities or it can be relative by 
comparison of the difference in cycle threshold values 
(Ct) of a unknown sample with respect to reference 
(mainly expressed as ∆∆Ct values)[12,13]. Finally, to 
improve the accuracy of measurements, qPCR offers, 
together with the basic reagents, a passive fluorescein 
or ROX dyes to remove well-factors. The fluorescein 
acts as a passive reference dye, providing sufficient 
background fluorescence before the amplification 
reaction occurs, removing in this way the well factors- 
such as pipetting inaccuracies and fluorescence 
fluctuations-from the plate with the test samples.
Quantification of total circulating cell-free DNA
Some studies have focused on the quantification of 
total cfDNA levels using GAPDH, Beta-globin, Beta2-
Microglobulin, hTERT or LINE-1 as potential target 
genes, making the higher levels of cfDNA as a way to 
distinguish benign from malignant BC[14–18]. Also SYBR 
Green’s fluorescence to measure total serum cfDNA 
has been investigated[19]. However, in our opinion, it 
is worth to consider how the total cfDNA levels are 
susceptible to increase also by the presence of other 
pathological conditions (e.g., infection, inflammation, 
etc.), thus influencing the results. 
Quantification of cell-free DNA integrity
The detection of ctDNA levels using cell-free DNA integrity 
(cfDI) measurement, as ratio between longer and shorter 
DNA fragments, is more specific than total serum cfDNA 
and has been explored in BC by qPCR by many authors 
using SYBRGreen fluorescent dye (Table 1). In principle, 
normal cells, undergoing apoptosis, release DNA 
fragments of about 200 bp as the result of enzymatic 
cleavage of nucleosome units; whereas, tumor cells 
undergo many different death processes, including 
necrosis and autophagy, and they can release DNA 
fragments of different sizes[20,21]. Umetani et al[22], 
using ALU targets proposed cfDI for the first time 
as a valuable tool to identify primary BC, showing it 
could be suitable to define lymph node metastasis in a 
group of 83 patients compared to 51 healthy controls. 
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They measured in serum shorter fragments of 115 
bp that were considered as derived from apoptotic 
normal cells and larger ones of 247 bp as ctDNA, 
derived from necrosis/autophagy of cancer cells. The 
cfDI value calculated as the ratio quantity of longer 
over shorter fragments, ALU247/ALU115, was found 
to be higher in BC patients with high grade cancer 
compared to healthy controls. Accordingly to Umetani 
et al[22], Agostini et al[23] using the same ALU247 bp 
and ALU115bp targets demonstrated in plasma that 
cfDI value was twice higher in BC patients (n = 39) 
vs healthy controls (n = 49). Subsequently, Stötzer 
et al[24] proved in plasma that the ratio ALU247/115 
were higher in patients with locally confined BC and 
MBC (n = 47) than benign BC (n = 12) (P < 0.001) 
but not vs healthy controls (n = 28). Moreover, this 
group evidenced that ALU concentrations alone were 
very interesting as markers for locally confined BC, 
while the use of cfDI was limited by the elevated levels 
found in some healthy controls. However, Iqbal et al[25] 
enrolling a larger number of women (148 patients vs 
51 healthy controls) confirmed that the cfDI value, 
represented as ALU247/115 ratio, was significantly 
higher in serum of patients compared to healthy 
controls. Moreover, through a multivariate analysis, 
they showed a correlation between the cfDI value and 
the tumor size to predict the overall survival (OS) at 
5 years and disease-free survival (DFS) at 4 years. 
Madhavan et al[21] also considered cfDI as a useful 
biomarker for BC in the largest patients’ cohort (82 BC 
and 201 MBC) by using different primer set for ALU 
sequences and introducing LINE-1 as another DNA 
repetitive element target. They quantified ALU 260 
bp and LINE-1 266 bp amplicons vs ALU 111 bp and 
LINE-197 bp amplicons, respectively. They showed, 
differently than the other groups, cfDI value was 
lower in BC patients vs healthy control and positively 
correlated with a decrease in progression-free survival 
(PFS) (P = 0.0025 for ALU) and OS (P < 0.0001 for 
both ALU and LINE-1). Similarly, using the same 
ALU260/111 and LINE-1 266/197 ratios, Cheng et al[26] 
showed that cfDI was significantly lower in recurrent 
BC (n = 37) vs non-recurrent BC (n = 175) (P < 
0.001 for both ALU and LINE-1 cfDI values) but they 
did not provide as an extra measure healthy controls. 
Interestingly, this latter research group showed that a 
higher risk of developing recurrence could be predicted 
by the reduction of cfDI value (P = 0.020 for ALU 
and P = 0.019 for LINE-1 cfDI values, respectively). 
Finally, it should be mentioned that Cheng et al[27] 
recently observed that higher cfDI values for both 
ALU and LINE-1 targets in MBC patients correlated 
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Circulating
tumour DNA
(ctDNA)
Cell free DNA
(cfDNA)
Quantification
of total cfDNA
Circulating tumour cells
(CTC); exosomes; miRNAs
and other non-coding
RNA, mRNAs
Blood sample
Figure 1  Diagram summarizing the possibility to monitor breast cancer from the blood circulating DNA.
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Table 1  cfDI evaluation for the monitoring of breast cancer
Targets, length of the amplicons and primers’ 
sequences
Patients with primary BC Results Ref.
ALU, 115 bp Healthy females (n = 51) and BC patients 
(n = 83) 
DNA from serum
The ratio ALU247/115 was higher in 51 
patients with stage II (P = 0.005), stage III 
(P < 0.0001), stage IV (0.002) compared to 
healthy controls but not in 32 patients with 
stage 0 or I
Umetani et al[22], 
2006 FW: 5’-CCTGAGGTCAGGAGTTCGAG-3’
RV: 5’-CCCGAGTAGCTGGGATTACA-3’
ALU, 247 bp
FW: 5’-GTGGCTCACGCCTGTAATC-3’ 
RV: 5’-CAGGCTGGAGTGCAGTGG-3’
ALU, 115 bp Healthy females (n = 49) and BC patients 
(n = 39)
DNA from plasma
In the group of patients the ratio 
ALU247/115 was twice higher (P < 0.0001) 
than in the group of healthy controls
Agostini et al[23], 
2012 FW: 5’-CCTGAGGTCAGGAGTTCGAG-3’ 
RV: 5’-CCCGAGTAGCTGGGATTACA-3’
ALU, 247 bp
FW: 5’-GTGGCTCACGCCTGTAATC-3’ 
RV: 5’-CAGGCTGGAGTGCAGTGG-3’
ALU, 115 bp Healthy females (n = 28), benign breast 
disease patients (n = 12), locally confined 
BC patients (n = 65) and MBC patients (n 
= 47)
DNA from plasma 
The ratio ALU247/115 was higher in 
patients with locally confined BC and 
metastatic BC than in benign BC (P < 0.001), 
but not vs healthy controls 
Stötzer et al[24], 
2014FW: 5’-CCTGAGGTCAGGAGTTCGAG-3’ 
RV: 5’-CCCGAGTAGCTGGGATTACA-3’
ALU, 247 bp
FW: 5’-GTGGCTCACGCCTGTAATC-3’ 
RV: 5’-CAGGCTGGAGTGCAGTGG-3’
ALU, 111 bp Healthy females (n = 100), primary BC 
patients (n = 82) and MBC patients (n = 
201)
DNA from plasma
Both the ratios ALU 260/111 and LINE-1 
266/97 were lower in primary BC patients 
(ALU: P = 0.046; LINE-1 P = 0.041)
In MBC patients the lower values of cfDI 
were related to both a decrease in PFS (P 
= 0.0025 for ALU) and OS (P < 0.0001 for 
both ALU and LINE-1 fragments)
Madhavan et al[21], 
2014 FW: 5’-CTGGCCAACATGGTGAAAC-3’
RV: 5’-AGCGATTCTCCTGCCTCAG-3’
ALU, 260 bp
FW: 5’-ACGCCTGTAATCCCAGCA-3’
RV: 5’-CGGAGTCTCGCTCTGTCG-3’
LINE-1, 97 bp
FW: 5’-TGGCACATATACACCATGGAA-3’
RV: 5’TGAGAATGATGGTTTCCAATTTC-3’
LINE-1, 266 bp
FW: 5’-ACTTGGAACCAACCCAAATG-3’
RV: 5’-CACCACAGTCCCCAGAGTG-3’
ALU, 115 bp Healthy females (n = 51) and BC patients 
(n = 148)
DNA from serum
The ratio ALU 247/115 was significantly 
higher in patients compared to controls (P 
< 0.001)
Iqbal et al[25], 2015
FW: 5’-CCTGAGGTCAGGAGTTCGAG-3’ 
RV: 5’-CCCGAGTAGCTGGGATTACA-3’
ALU, 247 bp
FW: 5’-GTGGCTCACGCCTGTAATC-3’ 
RV: 5’-CAGGCTGGAGTGCAGTGG-3’
Beta-actin, 100 bp Healthy females (n = 70), benign lesions 
(n = 95) and BC patients (n = 95)
DNA from plasma
cfDI value calculated as difference between 
400 bp and 100 bp fragments
Higher cfDI values were obtained in BC 
compared to benign lesions and healthy 
subjects (P < 0.001)
Kamel et al[20], 2016
FW: 5’-GCACCACACCTTCTACAATGA-3’
RV: 5’-GTCATCTTCTCGCGGTTGGC-3’
Beta-actin, 400 bp
FW: 5-GCACCACACCTTCTACAATGA-3’
(common primer)
RV: 5’-TGTCACGCACGATTTCCC-3’
HER2, 126 bp Healthy females (n = 10), BC patients (n 
= 79) 
DNA from serum
The ratios BCAS1 266/129, MYC 264/128, 
PIK3CA 274/129 were significantly higher 
in patients compared to controls (P = 0.002, 
P = 0.030 and P = 0.004, respectively)
No significant values for HER2 targets
Maltoni et al[28], 
2017FW-5-CCAGGGTGTTCCTCAGTTGT-3’
RV-5- -GGAGTTCCTGCAGAGGACAG-3’
HER2, 295 bp
FW-5’-CCAGGGTGTTCCTCAGTTGT-3’
RV-5’-TCAGTATGGCCTCACCCTTC-3’
MYC, 128 bp
FW-5-GGCATTTAAATTTCGGCTCA-3’ 
RV-5-AAAAGCCAAATGCCAACTT-3’
MYC, 264 bp
FW-5’-TGGAGTAGGGACCGCATATC-3’
RV-5’-ACCCAACACCACGTCCTAAC-3’
BCAS1, 129 bp
FW-5-GGGTCAGAGCTTCCTGTGAG-3’ 
RV-5-TATCATGCCTTGGAGAACCA-3’
BCAS1, 266 bp
FW-5’-GGGTCAGAGCTTCCTGTGAG-3’ 
RV-5’-CGTTGTCCTGAAACAGAGCA-3’ 
PIK3CA, 129 bp
FW-5’CTCCACGACCATCATCATCAGGT-3’ 
RV-5’-TGGTTATTAATGAGCCTCACGG-3’ 
PIK3CA, 274 bp
FW-5’-CTC CACGAC CAT CATCAGGT-3’ 
RV-5’-CGAAGGTCACAAAGTCGTCT-3’ 
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with longer PFS and OS. However, Kamel et al[20] 
measuring the 400 bp and 100 bp amplicons of the 
Beta-actin from the DNA derived from plasma of 
95 BC and 95 benign lesions vs 70 healthy controls 
estimated a cfDI- as difference between longer and 
shorter fragments- accordingly to Umetani et al[22] 
and the other authors[23-25], while yet differently from 
Madhavan et al[21]. In fact cfDI was found significantly 
higher in BC samples compared to those of benign and 
healthy subjects (P < 0.001). Moreover, they related 
those higher values to TNM stage, suggesting a cut-off 
to identify the more aggressive BC[20]. In agreement 
with Kamel et al[20], Maltoni et al[28] recently showed 
that tumour cells released longer DNA fragments than 
normal cells in the bloodstream. They quantified large 
fragments of 295 bp, 264 bp, 266 bp, 274 bp and 
short amplicons of 126, 128, 129, 129 bp from HER2, 
MYC, BCAS1 and PIK3CA, respectively, from the serum 
of healthy females (n = 10), non-recurrent BC (n = 
58) and recurrent BC (n = 21). They estimated cfDI 
as the ratio between longer and shorter amplicons of 
these genes and demonstrated that BCAS1, MYC and 
PIK3CA long/short amplicons were significantly higher 
in patients compared to healthy controls (P = 0.002, 
P = 0.030 and P = 0.004, respectively). On the other 
hand, there was no significant difference for long/short 
amplicons of HER2[27]. 
DISCUSSION
The overall literature on cfDI is intriguing as it has an 
extraordinary potential for the monitoring of BC, but 
it remains to be clarified what is the expected value 
of cfDI: some authors claimed that ctDNA is made 
of longer amplicons than normal cfDNA, explaining 
why the cfDI increased in BC[20,22-25,27], whereas other 
research groups, using different primers, claimed the 
exact opposite[21,26].
Most of the authors, in their measurement of 
cfDI through the ALU sequences, decided to use 
a standard DNA curve, as for Umetani et al[22], to 
derive quantifications of their DNA[21-25,27], and used 
the fluorescein or ROX passive reference dyes to 
improve the quality of their results[23,25]. Additionally, 
the specificities of the amplification reactions for the 
different couple of primers described in the papers 
have been controlled by means of denaturation 
curves or gel electrophoresis. This implies that the 
different results by qPCR hardly can be attributable 
to the laboratory’s methodology, although we cannot 
completely exclude some variability in sample 
collection in the studies here described. Of note, 
differently than the other groups, Stötzer et al[24] 
have adopted a slightly different protocol for ALU 
amplifications by introducing UDP-DNA glycosidase.
Higher cfDI values in BC vs healthy controls 
were found in larger patients’ cohorts derived from 
independent clinical settings and by using more 
different targets compared to studies claiming lower 
cfDI values in the tumor (Figure 2). Of note, higher 
cfDI in tumor than healthy controls were found in 
those studies that have analyzed mainly BCs, which 
did not reach the metastatic setting[22,23,25], whereas 
lower cfDI than healthy controls were reported in 
a study using the largest MBC patients’ cohort up-
to-date[21]. It is interesting to note that Umetani et 
al[22] proposed an increased cfDI value to predict 
local micrometastasis and recently Cheng et al[28] 
observed that cfDI value particularly decreased 
in BC patients with visceral metastasis. Thus we 
ALU, 111 bp Non-recurrent BC patients (n = 175)
vs recurrent-BC patients (n = 37)
No healthy females reported
DNA from plasma
Both the ratios ALU260/111 and 
LINE1-266/97 were significantly lower 
during follow-up in recurrent BC vs non 
recurrent BC (P < 0.001 for both ALU and 
LINE-1 cfDI), Moreover, BC patients with 
a lower cfDI had higher risk of developing 
recurrence compared to patients with 
higher cfDI (P = 0.020 for ALU cfDI and P 
= 0.019 for LINE-1 cfDI, respectively)
Cheng et al[26], 2017
FW: 5’-CTGGCCAACATGGTGAAAC-3’
RV: 5’-AGCGATTCTCCTGCCTCAG-3’
ALU, 260 bp
FW: 5’-ACGCCTGTAATCCCAGCA-3’
RV: 5’-CGGAGTCTCGCTCTGTCG-3’
LINE-1, 97 bp
FW: 5’-TGGCACATATACACCATGGAA-3’
RV: 5’-TGAGAATGATGGTTTCCAATTTC-3’
LINE-1, 266 bp
FW: 5’-ACTTGGAACCAACCCAAATG-3’
RV: 5’-CACCACAGTCCCCAGAGTG-3’
ALU, 111 bp MBC patients (total n = 268)
No healthy females
DNA from plasma
Both the ratios ALU260/111 and 
LINE1-266/97 significantly increased in 
268 MBC patients treated with one cycle 
of chemotherapy (MBCLB) compared to 
MBC at baseline (MBC1C) (P = 0.00017 for 
ALU -0.053 vs 0.063- and P = 0.0016 for 
LINE-1-0.45 vs 0.49)
Moreover, in both MBCBL and MBC1C 
patients with a higher cfDI (for both ALU 
and LINE-1) correlated with a higher PFS 
and OS vs lower cfDI MBC patients
Cheng et al[27], 2018
FW: 5’-CTGGCCAACATGGTGAAAC-3’
RV: 5’-AGCGATTCTCCTGCCTCAG-3’
ALU, 260 bp
FW: 5’-ACGCCTGTAATCCCAGCA-3’
RV: 5’-CGGAGTCTCGCTCTGTCG-3’
LINE-1, 97 bp
FW: 5’-TGGCACATATACACCATGGAA-3’
RV: 5’TGAGAATGATGGTTTCCAATTTC-3’
LINE-1, 266 bp
FW: 5’-ACTTGGAACCAACCCAAATG-3’
RV: 5’-CACCACAGTCCCCAGAGTG-3’
BC: Breast cancer; cfDNA: Cell-free DNA; cfDI: Cell-free DNA integrity; ctDNA: Circulating tumour DNA; DFS: Disease free survival; MBC: Metastatic 
breast cancer; PFS: Progression-free survival; OS: Overall survival; qPCR: Quantitative real-time PCR; ddPCR: Droplet digital PCR.
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suggest that cfDI value can increase at initial stages 
of the BC and decrease in MBC. Surely, the most 
promising targets for the measurement of cfDI are 
represented by repetitive elements such as ALU and 
LINE-1 sequences, accounting for nearly 10% and 
17% of the total genome, respectively. It is worth 
nothing that reproducible results were obtained when 
independent groups used the same ALU primer pairs, 
either those demonstrating higher cfDI[22-25] and those 
demonstrating lower cfDI in BC[21,26]. In our opinion, 
the methods of DNA extractions merely could have 
influenced the results. Interestingly, by looking with 
BLASTN genomic RefSeqGene Human at the target 
sites of ALU primers’ pairs used by the research groups 
obtaining divergent results, we observed different 
target sites for ALU247/115 pairs compared to the 
ALU260/111 ones. We cannot exclude that this could 
contribute to the opposite cfDI values obtained by the 
different research groups comparing BC vs healthy 
controls. Moreover, we would like to point out that 
the qPCR methodology by SYBR Green is not very 
sensitive in quantifying very small DNA fragments 
in diluted solutions[29], as it could be in liquid biopsy, 
and that the variability of amplification efficiency of 
a sample can be overtaken by many replicates and 
independent experiments, that are hard to performed 
with samples derived from liquid biopsy. In this 
respect, the determination of cfDI in liquid biopsy 
samples would benefit by more sensitive and accurate 
technologies such as digital droplet PCR (ddPCR).
In conclusion, monitoring primary and MBC through 
a non-invasive analysis such as that of circulating 
DNA remains one of the most interesting goals to 
achieve. Surely, the mutations in liquid biopsy are of 
paramount importance for targeted therapies and for 
monitoring response to treatment. However, the most 
interesting benefit-to-cost analysis for the follow-up 
of BC and its recurrence seems to be the evaluation 
of circulating cfDI. Future investigations for cfDI 
by ddPCR are warranted for the (1) testing for the 
choice of best targets; (2) clarification of the clinical 
significance of larger and shorter DNA fragments origin 
in serum/plasma; and (3) a better understanding 
of the potential clinical impact of cfDI in anticipating 
recurrence and responsiveness to therapies for all 
patients, independently from the mutational signature 
of BC. 
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